Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
One Percent Rule Checklist For Safer Forex Trading Risk 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
The U.S. Federal Circuit Court of Appeals in Washington, D.C. reinstated a 2017 jury verdict ordering Teva Pharmaceutical Industries Ltd to pay $235.5 million to GlaxoSmithKline Plc for selling a generic version of a heart drug, covered by the latter's patent.
In a 2-1 decision, the appeals court found “substantial evidence” that Teva induced doctors to prescribe its generic tablets.
Israeli drugmaker Teva plans to appeal and introduce additional defenses that it neither infringed nor induced doctors to infringe Glaxo’s patent.
The case arose after Teva began selling a generic version of Coreg, which Glaxo had won U.S. approval for, in 2007.
Coreg treats hypertension, left ventricular dysfunction after a heart attack, and congestive heart failure.
In 2017, a Delaware jury ordered the to pay $234.1 million for lost profit plus $1.4 million in royalties.
US District Judge Leonard Stark overturned the verdict due to other factors that could have caused doctors to prescribe Coreg.
But Circuit Judge Pauline Newman said Teva's promotional materials, product catalogs, the FDA labels, press releases, and witness testimony supported allegations of “induced infringement.”
